The activator targeted NCX1 and NCX3 has been demonstrated to display neuroprotection in preclinical models of cerebral ischemia via upregulation of the PI3K-Akt signaling pathway [69,70]. The gene discussed is SLC8A3; the disease is brain ischemia.